Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) and C4 Therapeutics (NASDAQ:CCCC – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.
Profitability
This table compares Fennec Pharmaceuticals and C4 Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fennec Pharmaceuticals | -2.30% | -53.38% | -2.08% |
| C4 Therapeutics | -313.35% | -42.45% | -27.55% |
Institutional & Insider Ownership
55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 11.0% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Analyst Recommendations
This is a breakdown of current recommendations for Fennec Pharmaceuticals and C4 Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fennec Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
| C4 Therapeutics | 0 | 3 | 3 | 0 | 2.50 |
Fennec Pharmaceuticals currently has a consensus price target of $13.67, suggesting a potential upside of 105.51%. C4 Therapeutics has a consensus price target of $11.60, suggesting a potential upside of 285.38%. Given C4 Therapeutics’ higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Fennec Pharmaceuticals.
Valuation and Earnings
This table compares Fennec Pharmaceuticals and C4 Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fennec Pharmaceuticals | $49.35 million | 3.71 | -$16.05 million | ($0.10) | -66.50 |
| C4 Therapeutics | $20.76 million | 10.23 | -$132.49 million | ($1.70) | -1.77 |
Fennec Pharmaceuticals has higher revenue and earnings than C4 Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Fennec Pharmaceuticals beats C4 Therapeutics on 8 of the 14 factors compared between the two stocks.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
About C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
